Trokendi XR
Drug - Trokendi XR™ (topiramate capsule, extended-release) [Supernus Pharmaceuticals Inc.]
June 2017
Therapeutic area - Antiepileptics
Approval criteria
- is 6 years of age or older AND
- Patient has one of the following diagnoses: partial onset seizures; primary generalized tonic/clonic seizures; Lennox-Gastaut syndrome AND
- Patient has had a two-month trial of immediate-release topiramate OR
- Patient is 12 years of age or older AND
- Patient is prescribed Trokendi XR for prophylaxis of migraine headache AND
- Patient has had a two-month trial of immediate-release topiramate
Quantity limit
- If approved for qualified seizure disorder diagnosis
- 200mg: 68 capsules per 34 days
- 25mg, 50mg, 100mg: 102 capsules per 34 days
- If approved for qualified migraine headache prophylaxis diagnosis
- 25mg, 50mg: 68 capsules per 34 days
- 100 mg capsules: 34 capsules per 34 days
Additional information
Trokendi XR™ is only indicated for treatment of specific seizure disorders and for prophylaxis of migraine headache. Appropriate diagnosis of seizures will be required for approval; use in neuralgia or bipolar disorder will not be approved.
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411